These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 2137942)

  • 1. Dopamine control of seizure propagation: intranigral dopamine D1 agonist SKF-38393 enhances susceptibility to seizures.
    Turski WA; Cavalheiro EA; Ikonomidou C; Bortolotto ZA; Klockgether T; Turski L
    Synapse; 1990; 5(2):113-9. PubMed ID: 2137942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SKF 38393 alters the rate-dependent D2-mediated inhibition of nigrostriatal but not mesoaccumbens dopamine neurons.
    Kelland MD; Freeman AS; Chiodo LA
    Synapse; 1988; 2(4):416-23. PubMed ID: 2973142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-1 dopamine agonist administration reduces the threshold for convulsions produced by pilocarpine.
    Barone P; Palma V; Parashos SA; Marin C; Chase TN; Campanella G
    Boll Soc Ital Biol Sper; 1989 Apr; 65(4):337-41. PubMed ID: 2570598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ; Marshall JF
    Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX; Walters JR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.
    DeBoer P; Abercrombie ED
    J Pharmacol Exp Ther; 1996 May; 277(2):775-83. PubMed ID: 8627558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nigrostriatal lesion alters neurophysiological responses to selective and nonselective D-1 and D-2 dopamine agonists in rat globus pallidus.
    Carlson JH; Bergstrom DA; Demo SD; Walters JR
    Synapse; 1990; 5(2):83-93. PubMed ID: 2309160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D1 receptor activation enhances sciatic nerve stimulation-induced inhibition of nigrostriatal dopamine neurons.
    Kelland MD; Freeman AS; Chiodo LA
    Synapse; 1989; 3(4):339-45. PubMed ID: 2525823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proconvulsant effect of SKF 38393 mediated by nigral D1 receptors.
    al-Tajir G; Starr MS; Starr BS
    Eur J Pharmacol; 1990 Jul; 182(2):245-51. PubMed ID: 2204536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
    Calabresi P; Mercuri NB; Sancesario G; Bernardi G
    Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of GABA release by dopamine in the substantia nigra.
    Matuszewich L; Yamamoto BK
    Synapse; 1999 Apr; 32(1):29-36. PubMed ID: 10188635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurophysiological investigation of effects of the D-1 agonist SKF 38393 on tonic activity of substantia nigra dopamine neurons.
    Carlson JH; Bergstrom DA; Weick BG; Walters JR
    Synapse; 1987; 1(5):411-6. PubMed ID: 2975067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of full D1 dopamine receptor agonists on firing rates in the globus pallidus and substantia nigra pars compacta in vivo: tests for D1 receptor selectivity and comparisons to the partial agonist SKF 38393.
    Ruskin DN; Rawji SS; Walters JR
    J Pharmacol Exp Ther; 1998 Jul; 286(1):272-81. PubMed ID: 9655869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D; Osborn CV
    Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates.
    Byrnes EM; Bruno JP
    Dev Psychobiol; 1994 Sep; 27(6):409-24. PubMed ID: 8001729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.